Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 10 chart positions in 10 markets.
By chart position
- 🇨🇦CA · Courses#1525K to 30K
- 🇧🇷BR · Courses#6710K to 30K
- 🇯🇵JP · Courses#7410K to 30K
- 🇸🇪SE · Courses#7510K to 30K
- 🇰🇷KR · Courses#1061K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
14K to 52K🎙 Daily cadence·242 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
48K to 172K🇨🇦17%🇧🇷17%🇯🇵17%+7 more - Active Followers
Loyal subscribers who consistently listen
19K to 69K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 17 epsHosts
Recent guests
Recent episodes
Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
Jun 22, 2026
Unknown duration
Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness
Jun 9, 2026
27m 23s
HNSCC: Current and Emerging Therapeutic Strategies
May 29, 2026
26m 24s
Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies
May 15, 2026
20m 50s
Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma
May 7, 2026
31m 00s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/22/26 |  Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider | This podcast features nurse practitioner Elizabeth Krueger and physician associate Sam Vafadar, discussing their approaches to individualizing first-line treatment options for patients with EGFR-mutated NSCLC based on the latest evidence and how they work with patients to promote adherence and manage adverse events. | — | ||||||
| 6/9/26 |  Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness✨ | lung cancer screeningearly detection+4 | expert | Decera Clinical Educationlow-dose CT screening | lung cancer | lung cancerscreening+5 | — | 27m 23s | |
| 5/29/26 |  HNSCC: Current and Emerging Therapeutic Strategies✨ | HNSCC treatmenttherapeutic strategies+4 | Dr Deborah Wong | head and neck squamous cell carcinomaIO-based therapy+8 | — | HNSCCtreatment strategies+5 | — | 26m 24s | |
| 5/15/26 |  Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies✨ | multiple myelomabispecific antibodies+3 | Doris K. Hansen, MD | — | — | multiple myelomabispecific antibodies+5 | — | 20m 50s | |
| 5/7/26 |  Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma✨ | bispecific antibody therapyrelapsed/refractory multiple myeloma+3 | Muhamed Baljevic, MD, FACPJohnathan Ticku, MD | bispecific antibodiestocilizumab+2 | — | oncologymultiple myeloma+3 | — | 31m 00s | |
| 4/30/26 |  Thrombotic Events and ET/PV: What You Should Know✨ | thrombotic eventspolycythemia vera+4 | Anthony M. Hunter, MDDouglas Tremblay, MD | Decera Clinical Education | — | thrombotic eventsPV+5 | — | 22m 08s | |
| 4/30/26 |  Global Experts Discuss Current and Emerging Treatments for ET and PV✨ | essential thrombocythemiapolycythemia vera+4 | Ciro Rinaldi MD, PhDAlessandro M. Vannucchi, MD | Decera Clinical Education | — | ETPV+5 | — | 17m 21s | |
| 4/29/26 |  Global Experts Discuss Diagnostic Considerations in ET and PV✨ | diagnosisessential thrombocythemia+3 | Ciro Rinaldi, MD, PhDAlessandro M. Vannucchi, MD | Global Experts Discuss Diagnostic Considerations in ET and PV | — | diagnostic considerationsET+3 | — | 14m 55s | |
| 4/17/26 |  Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer✨ | HER2-positive metastatic breast cancerfirst-line therapy+3 | Erika Hamilton, MD, FASCOIan Krop, MD, PhD | Decera Clinical Education | — | HER2-positivemetastatic breast cancer+3 | — | 22m 41s | |
| 4/15/26 |  Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes✨ | patient carebreast cancer+4 | patient advocateearly breast cancer survivor | Decera Clinical Education | — | breast cancerpatient advocacy+5 | — | 41m 42s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/15/26 |  Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities✨ | AKT inhibitorsPI3K inhibitors+5 | Nadia Harbeck, MDFrancois-Clement Bidard, MD, PhD | Decera Clinical Education | — | AKT inhibitorsPI3K inhibitors+5 | — | 31m 22s | |
| 4/14/26 |  Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer✨ | patient-centered strategiesCDK4/6 inhibitor therapy+4 | — | CDK4/6 inhibitor therapyDecera Clinical Education | HR-positive/HER2-negative breast cancer | CDK4/6 inhibitorsbreast cancer+4 | — | 44m 46s | |
| 4/13/26 |  TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions✨ | TROP2-directed therapynon-small-cell lung cancer+3 | — | TROP2-directed antibody-drug conjugatesNSCLC+1 | — | TROP2antibody-drug conjugates+4 | — | 33m 13s | |
| 4/13/26 |  Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer✨ | emerging therapiesHER2-positive cancer+3 | Amit Mahipal, MD, MPHShubham Pant, MD | Decera Clinical EducationHER2+ Gastroesophageal Adenocarcinoma+1 | — | HER2-positivegastroesophageal adenocarcinoma+3 | — | 39m 12s | |
| 3/26/26 |  Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC✨ | HER2-negative breast cancermetastatic breast cancer+3 | Aditya Bardia, MD, MPH, FASCORuta Rao, MD | Decera Clinical Education | — | HER2-negativemetastatic breast cancer+3 | — | 19m 16s | |
| 3/25/26 |  Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer✨ | biomarker testingcolorectal cancer+3 | advanced practice professionals | Decera Clinical Education | colorectal cancer | biomarker testingcolorectal cancer+3 | — | 33m 23s | |
| 3/25/26 |  Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer✨ | biomarker testingsolid tumors+3 | — | Decera Clinical Education | Prostate Cancer | biomarker testingprostate cancer+4 | — | 22m 19s | |
| 3/23/26 |  Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026✨ | bladder cancertreatment options+4 | — | ASCOBCG+2 | NMIBC | bladder cancertreatment+6 | — | 18m 57s | |
| 3/20/26 |  Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization | Listen to oncology pharmacists, Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, discuss assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, providing their experiences using these therapies for their patients with early-stage breast cancer. | — | ||||||
| 3/11/26 |  From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL | This episode features Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discussing key conference highlights from the 2025 ASH Annual Meeting, with a focus on emerging BTK-targeted therapies in relapsed/refractory CLL. They share global perspectives on real-world use, sequencing strategies, safety considerations, and how new data may shape future clinical practice. | — | ||||||
| 3/9/26 |  2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast | Listen to breast cancer experts discussing clinical highlights from a recent webinar on new data and clinical updates presented at the 2025 San Antonio Breast Cancer Symposium, including answers to outstanding questions in the field of breast cancer care. | — | ||||||
| 3/9/26 |  Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions | In this episode, 2 experts discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including the clinical impact of first-generation therapies and challenges related to resistance. They also explore emerging next-generation inhibitors and combination strategies that may expand treatment options and improve patient outcomes. | — | ||||||
| 2/27/26 |  Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies | In this episode, 2 experts discuss how immunotherapy has reshaped the treatment landscape of acute lymphoblastic leukemia (ALL), highlighting advances in bispecific antibodies, CAR T-cell therapies, and MRD-guided strategies in both frontline and relapsed/refractory settings. They also explore evolving decisions around toxicity, treatment sequencing, transplant, and the promise of more effective, less burdensome approaches that may further improve long-term outcomes. | — | ||||||
| 2/23/26 |  Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer | Listen to Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, as they discuss novel RAS-targeted therapies for pancreatic cancer, including optimal KRAS mutation testing, emerging multiselective RAS inhibitors, and combination strategies. | — | ||||||
| 2/20/26 |  Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer | Listen to this podcast with advanced practice professionals providing an overview of the current biomarker testing landscape for patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer. | — | ||||||
Showing 25 of 250
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
10 placements across 10 markets.
Chart Positions
10 placements across 10 markets.